Lupin & Cornerstone End Development Agreement

Lupin Ltd has announced that the Company and Cornerstone BioPharma, Inc, had, in May 2005, entered into an agreement to co-develop an antiinfective for the United States market.

Both parties have now mutually agreed to end the co development agreement.

The Company plans to continue the product development program and will seek a partner to market the product to primary care physicians in the US.

Source : Equity Bulls

Keywords